SIRT2 and neoplasm: SJ-106C, while still inhibiting SIRT1and SIRT2, is enriched in the mitochondria to help with SIRT3 inhibition.It is more active against DLBCL than other solid tumor cells and effectivelyinhibits DLBCL xenograft tumor growth.